Company: INDP
Filing Date: 2025-06-13
Form Type: PRE 14A
Source: 0001641172-25-014978
Chunk: 5

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-06-13
Form: PRE 14A
Chunk 5
---
 Biosystems, Inc., the entity acquired by Indaptus in
connection with the merger with Decoy.

<div align='center'>IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON JULY 25, 2025

This Proxy Statement is available at http://www.proxyvote.com/</div>

Proposals

At the Special Meeting, our stockholders will
be asked:

| ● | To approve, in accordance with Nasdaq                                                                                                    
 Listing Rule 5635(d), the issuance of (i) shares of the Company’s common stock issuable upon the conversion of convertible               
 notes (“Notes”) issued or issuable in an ongoing private placement under Rule 506(c) of the Securities Act of 1933, as                   
 amended (the “Private Placement”), and (ii) shares of common stock issuable upon exercise of certain warrants including                  
 (“Common Warrants”) pre-funded warrants issuable in lieu of shares of common stock issuable upon conversion of the Notes                 
 (“Pre-funded Warrants”), and placement agent warrants (“Placement Agent Warrants”), each of which is issuable                            
 in the Private Placement (the “Issuance Proposal”);                                                                                      |
| ● | To approve, in accordance with Nasdaq Listing Rule 5635(c),                                                                              
 the issuance of (i) shares of common stock issuable upon the conversion of one or more Notes issued or issuable in the Private Placement 
 to the Chief Executive Officer and Director of the Company (“Related Party”), and (ii) shares of common stock issuable                   
 upon exercise of one or more Common Warrants issuable in the Private Placement to the Related Party (the “Related Party Proposal”);      
 and                                                                                                                                      |

<div align='center'>2</div>

| ● | To transact such other business as may properly come before the Special           
 Meeting or any continuation, postponement, or adjournment of the Special Meeting. |

We know of no other business that will be presented
at the Special Meeting. If any other matter properly comes before the stockholders for a vote at the Special Meeting, however, the proxy
holders named on the Company’s proxy card will vote your shares in accordance with their best judgment.

Recommendations of the Board

The Board of Directors recommends that you vote
your shares as indicated below. If you return a properly completed proxy card, or vote your shares by telephone or Internet, your shares
of common stock will be voted on your behalf as you